{"id":"NCT00680017","sponsor":"AstraZeneca","briefTitle":"30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease","officialTitle":"A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects With Stage 3 Chronic Kidney Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2011-04","completion":"2011-04","firstPosted":"2008-05-19","resultsPosted":"2012-07-16","lastUpdate":"2012-10-03"},"enrollment":280,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dyslipidemia","Kidney Disease"],"interventions":[{"type":"DRUG","name":"ABT-335 plus rosuvastatin","otherNames":["fenofibric acid and rosuvastatin"]},{"type":"DRUG","name":"Rosuvastatin","otherNames":["rosuvastatin, Crestor"]}],"arms":[{"label":"ABT-335 plus rosuvastatin","type":"EXPERIMENTAL"},{"label":"Rosuvastatin","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to evaluate the safety and efficacy of the combination of ABT-335 plus rosuvastatin in dyslipidemic subjects with Chronic Kidney Disease (CKD) Stage 3.","primaryOutcome":{"measure":"Median Percent Change in Triglycerides From Baseline to Week 8.","timeFrame":"Baseline to 8 weeks","effectByArm":[{"arm":"ABT-335 Plus Rosuvastatin","deltaMin":-38,"sd":null},{"arm":"Rosuvastatin","deltaMin":-22.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":114,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["38018702","23891363"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":140},"commonTop":["Oedema Peripheral","Headache","Cough","Diarrhoea","Glomerular Filtration Rate Decreased"]}}